A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Key facts
- Where
- Brampton, North York, Saint-Charles-Borromée, Sarnia, Scarborough Village, Surrey, Toronto, and Vancouver, CanadaSee the 8 sites
- Phase
- Phase 3
Where in Canada
- BramptonBrampton, CanadaNot yet recruiting
- North YorkNorth York, CanadaNot yet recruiting
- Saint-Charles-BorroméeSaint-Charles-Borromée, CanadaNot yet recruiting
- SarniaSarnia, CanadaNot yet recruiting
- Scarborough VillageScarborough Village, CanadaNot yet recruiting
- SurreySurrey, CanadaNot yet recruiting
- TorontoToronto, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07664553EU 2025-523935-20-00
- Record updated
- 4 August 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Inclusion: Diagnosed with T2DM for at least 90 days prior to screening; Stable treatment with background insulin and other background glucose-lowering medication(s); HbA1c value of ≥ 7% to ≤ 10.5%; Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (NYHA IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.